AAN: Half of Premenopausal Women Have Menstrual Migraines
By Lori Solomon HealthDay Reporter
FRIDAY, April 19, 2024 – More than half of premenopausal women report menstrual migraine (MM), according to a study presented at the annual meeting of the American Academy of Neurology, held from April 13 to 18 in Denver.
Jessica Cirillo, from Pfizer in New York City, and colleagues estimated the prevalence of MM and identified characteristics of women with MM. The analysis included data from the 2021 U.S. National Health and Wellness Survey.
The researchers estimate that 6.2 million women have MM, with a prevalence of 31.0 percent among all women and 52.5 percent among premenopausal women. Women with MM were a mean age of 33.2 years, 52.6 percent were married/partnered, 66.6 percent were employed, and 38.2 percent had obesity. On average, reported monthly migraine attack frequency was 4.5 days and reported monthly migraine headache days were 8.4 days. More than half of women with MM (56.2 percent) had moderate-to-severe migraine-specific disability. For women with MM, 42.4 percent treated headaches using only over-the-counter medications and 48.6 percent used prescription medications. More women reported only acute migraine treatments (63.9 percent) than migraine prevention (21.1 percent). Triptans (36.7 percent; 3.9 days of use), nonsteroidal anti-inflammatory drugs (31.1 percent; 8.1days), and opioids (22.2 percent; 7.9 days) were the most common acute treatments reported.
“The first step in helping a woman with menstrual migraine is making a diagnosis; the second part is prescribing a treatment; and the third part is finding treatments patients are satisfied with and remain on to reduce disability and improve quality of life," coauthor, Jessica Ailani M.D., from Georgetown University in Washington, D.C., said in a statement.
Several authors disclosed financial ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Use of Acid-Suppression Therapy Linked to Migraine, Severe Headache
FRIDAY, April 26, 2024 -- Use of acid-suppression therapy is associated with higher odds of migraine or severe headache, according to a study published online April 24 in...
American Academy of Neurology, April 13-18
The annual meeting of the American Academy of Neurology was held this year from April 13 to 18 in Denver, drawing participants from around the world, including clinicians...
Use of CT Angiogram on the Rise for Headache, Dizziness in Emergency Department
WEDNESDAY, April 17, 2024 -- There was a 67.4 percent increase in head and neck computed tomography angiography (CTA) ordering for emergency department patients presenting for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.